Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer HealthCare and Inception Sciences announce eye disease alliance

Bayer HealthCare and Inception Sciences announce eye disease alliance

21st November 2013

Bayer HealthCare has announced a new collaboration with Inception Sciences and Versant Ventures in the field of ophthalmology.

The companies will band together to found a new joint venture called Inception 4, which will focus on the creation of innovative treatment options for patients with eye diseases such as wet age-related macular degeneration and geographic atrophy.

An early research project will be undertaken that will leverage Inception Science's capabilities and scientific expertise, with Versant Ventures providing equity funding and Bayer offering milestone payments.

This will aid Bayer HealthCare's efforts to create new therapies for retinal eye diseases, including a promising novel drug candidate with an alternative mode of delivery as an eye drop.

Professor Andreas Busch, head of global drug discovery and a member of the executive committee of Bayer HealthCare, said: "If successfully developed and later approved, this could provide a convenient treatment option for patients suffering from wet age-related macular degeneration."

This comes after the firm announced positive clinical data earlier this week showing the benefits of its eye drug VEGF Trap-Eye in the treatment of myopic choroidal neovascularisation.ADNFCR-8000103-ID-801663300-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.